Literature DB >> 25749390

EPA guidance on the early intervention in clinical high risk states of psychoses.

S J Schmidt1, F Schultze-Lutter1, B G Schimmelmann1, N P Maric2, R K R Salokangas3, A Riecher-Rössler4, M van der Gaag5, A Meneghelli6, M Nordentoft7, M Marshall8, A Morrison9, A Raballo10, J Klosterkötter11, S Ruhrmann12.   

Abstract

This guidance paper from the European Psychiatric Association (EPA) aims to provide evidence-based recommendations on early intervention in clinical high risk (CHR) states of psychosis, assessed according to the EPA guidance on early detection. The recommendations were derived from a meta-analysis of current empirical evidence on the efficacy of psychological and pharmacological interventions in CHR samples. Eligible studies had to investigate conversion rate and/or functioning as a treatment outcome in CHR patients defined by the ultra-high risk and/or basic symptom criteria. Besides analyses on treatment effects on conversion rate and functional outcome, age and type of intervention were examined as potential moderators. Based on data from 15 studies (n=1394), early intervention generally produced significantly reduced conversion rates at 6- to 48-month follow-up compared to control conditions. However, early intervention failed to achieve significantly greater functional improvements because both early intervention and control conditions produced similar positive effects. With regard to the type of intervention, both psychological and pharmacological interventions produced significant effects on conversion rates, but not on functional outcome relative to the control conditions. Early intervention in youth samples was generally less effective than in predominantly adult samples. Seven evidence-based recommendations for early intervention in CHR samples could have been formulated, although more studies are needed to investigate the specificity of treatment effects and potential age effects in order to tailor interventions to the individual treatment needs and risk status.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Adolescents; Antipsychotics; Cognitive-behavioral therapy; Early intervention in Europe; Meta-analysis; Neuroprotective; Prevention; Psychosis; Risk; Youth

Mesh:

Substances:

Year:  2015        PMID: 25749390     DOI: 10.1016/j.eurpsy.2015.01.013

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  90 in total

1.  [Should antipsychotics be used in prodromal stages of schizophrenia to prevent psychosis? Pro].

Authors:  M Lambert; C Correll
Journal:  Nervenarzt       Date:  2015-11       Impact factor: 1.214

2.  [Should antipsychotics be used in prodromal stages of schizophrenia to prevent psychosis? Con].

Authors:  A Bechdolf; S Laier; M Kallenbach; A Biester; K Leopold
Journal:  Nervenarzt       Date:  2015-11       Impact factor: 1.214

3.  Clinical high risk for psychosis in childhood and adolescence: findings from the 2-year follow-up of the ReARMS project.

Authors:  Michele Poletti; Lorenzo Pelizza; Silvia Azzali; Federica Paterlini; Sara Garlassi; Ilaria Scazza; Luigi Rocco Chiri; Eva Gebhardt; Simona Pupo; Raballo Andrea
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-12-01       Impact factor: 4.785

Review 4.  Physical Health and Drug Safety in Individuals with Schizophrenia.

Authors:  Tamara Pringsheim; Martina Kelly; Doug Urness; Michael Teehan; Zahinoor Ismail; David Gardner
Journal:  Can J Psychiatry       Date:  2017-07-18       Impact factor: 4.356

5.  Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis.

Authors:  Cathy Davies; Andrea Cipriani; John P A Ioannidis; Joaquim Radua; Daniel Stahl; Umberto Provenzani; Philip McGuire; Paolo Fusar-Poli
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

Review 6.  Canadian Guidelines for the Assessment and Diagnosis of Patients with Schizophrenia Spectrum and Other Psychotic Disorders.

Authors:  Donald Addington; Sabina Abidi; Iliana Garcia-Ortega; William G Honer; Zahinoor Ismail
Journal:  Can J Psychiatry       Date:  2017-07-21       Impact factor: 4.356

Review 7.  Canadian Treatment Guidelines for Individuals at Clinical High Risk of Psychosis.

Authors:  Jean Addington; Donald Addington; Sabina Abidi; Thomas Raedler; Gary Remington
Journal:  Can J Psychiatry       Date:  2017-07-21       Impact factor: 4.356

Review 8.  Guidelines for the Pharmacotherapy of Schizophrenia in Adults.

Authors:  Gary Remington; Donald Addington; William Honer; Zahinoor Ismail; Thomas Raedler; Michael Teehan
Journal:  Can J Psychiatry       Date:  2017-07-13       Impact factor: 4.356

9.  The Global Functioning: Social and Role Scales-Further Validation in a Large Sample of Adolescents and Young Adults at Clinical High Risk for Psychosis.

Authors:  Ricardo E Carrión; Andrea M Auther; Danielle McLaughlin; Ruth Olsen; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Barbara A Cornblatt
Journal:  Schizophr Bull       Date:  2019-06-18       Impact factor: 9.306

Review 10.  Progress and Future Directions in Research on the Psychosis Prodrome: A Review for Clinicians.

Authors:  Kristen A Woodberry; Daniel I Shapiro; Caitlin Bryant; Larry J Seidman
Journal:  Harv Rev Psychiatry       Date:  2016 Mar-Apr       Impact factor: 3.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.